By Digitalis Ventures
April 23, 2020
Portfolio
April 23, 2020
On April 6, 2020, Second Genome announced a four-year strategic collaboration with Gilead Sciences in identifying biomarkers associated with the clinical response to Gilead drugs in development. Second Genome, a leader in microbiome science, utilizes its proprietary Microbiome Analytics Platform to discover novel metabolites and enable precision medicine for patient stratification. With this strategic partnership, the two companies are focusing on drug candidates relevant to inflammatory disease and particularly Inflammatory Bowel Disease, where patients face significant challenges given the current available therapeutics.
To learn more, see the full press release here.